Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof

A technology for ulcerative colitis and colon targeting, which is applied in the field of medicine, can solve the problems of affecting the efficacy of drugs and not being able to reach them, and achieve the effects of improving gastrointestinal function, low cost, and promoting the absorption of nutrients

Active Publication Date: 2011-06-08
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After oral administration of ordinary tablets and capsules, the drug has been absorbed or degraded by the whole body before reaching the colon; after rectal administration of traditional Chinese medicine external treatment preparations such as suppositories and enemas, the drug is limited to the rectum and descending colon, and cannot reach the transverse colon, ascending colon, etc. Major ulcer lesions such as the colon affect the efficacy of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof
  • Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1 prepares pharmaceutical composition of the present invention

[0043] 1) Take according to weight ratio: 30 parts of Atractylodes Rhizome, 30 parts of Coptis Rhizoma, and 30 parts of Fangfeng, decoct them into oral solution and pack them separately according to the routine.

[0044] 2) Take respectively according to the weight ratio: 45 parts of Atractylodes Rhizome, 40 parts of Coptis Rhizoma, and 45 parts of Fangfeng, decoct them into oral solution and pack them separately according to the routine.

[0045] 3) Take respectively according to the weight ratio: 55 parts of Atractylodes Rhizome, 40 parts of Coptis Rhizoma, and 60 parts of Fangfeng, decoct them into oral solution and pack them separately according to the routine.

Embodiment 2

[0046] Embodiment 2 prepares a kind of Atractylodes Rhizoma Coptidis pellet preparation

[0047] 1. Preparation of Atractylodes macrocephala volatile oil

[0048] Take 600g of Atractylodes macrocephala, pulverize it into a coarse powder, put it into a supercritical extraction reaction kettle, the extraction temperature is 50°C, the extraction pressure is 35MPa, CO 2 The flow rate is 3L·h -1 , the extraction time was 3h, and the extracted product was collected to obtain 29.7g of Atractylodes macrocephala volatile oil;

[0049] 2. Preparation of Parsnip Extract

[0050] Take 600g of the windproof medicinal material, grind it into coarse powder, put it in an ultrasonic extractor, add 6 times the weight of 75% ethanol aqueous solution, ultrasonically extract twice, 30min each time, filter and combine the extracts, recover the ethanol under reduced pressure and dry it to obtain Wind extract 17.4g;

[0051] 3. Preparation of Cyclodextrin Inclusion Compound of Atractylodes Rhizom...

Embodiment 3

[0065] Embodiment 3 prepares a kind of Atractylodes Rhizoma Coptidis pellet preparation

[0066] The weight ratio of each component of this Atractylodes Rhizoma Coptidis pellet preparation is:

[0067] Atractylodes macrocephala extract: 36 parts,

[0068] Berberine: 7 parts,

[0069] Parsnip Extract: 21 parts.

[0070] The preparation method is the same as in Example 2.

[0071] Drug efficacy evaluation:

[0072] Ulcerative colitis model rats are selected to evaluate the efficacy of the drug of the present invention.

[0073] 1. Experimental animals

[0074] Healthy male SD rats, clean grade, weighing 180g-200g, were purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences, animal certificate number: [SYXK (Shanghai) 2002-0026], free to eat and drink.

[0075] 2. Test drug

[0076] The pharmaceutical composition of the present invention (abbreviated as BHF) is prepared by (1) of Example 1;

[0077] TNBS was purchased from Sigma Company as a 5% (w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for treating ulcerative colitis and a micro-pill preparation with colon-targeted properties thereof, relating to the technical field of medicines. The pharmaceutical composition takes bighead atractylodes rhizome as a monarch medicine, coptis as a ministerial medicine and radix sileris as an adjuvant medicine, and is prepared from the following components in concrete parts by weight: 30-60 parts of bighead atractylodes rhizome, 30-45 parts of coptis and 30-60 parts of radix sileris. The extracts of the bighead atractylodes rhizome, coptis and radix sileris are respectively prepared into stomach-soluble micro-pills and intestine-soluble micro-pills, and then, the stomach-soluble micro-pills and the intestine-soluble micro-pills are proportionally mixed to prepare an oral colon-targeted administration system of micro-pills prepared from bighead atractylodes rhizome and coptis, thereby realizing the purpose of colon-targeted administration and better exerting the effect of the composition. The pharmaceutical composition provided by the invention and the oral colon-targeted administration system of micro-pills prepared from bighead atractylodes rhizome and coptis have the dual-treatment characteristics of treating both principal and secondary aspects of diseases and simultaneously considering overall and local aspects, and are safe and convenient in oral administration and low is cost. The animal experiment shows that the pharmaceutical composition and the oral colon-targeted administration system have an obvious treatment effect on ulcerative colitis (the treatment effect is close to or even superior to the treatment effect of a positive control medicine salicylazosulfapyridine (SASP)), and have small side effects, thus the pharmaceutical composition and the oral colon-targeted administration system can be used for preparing medicines for treating ulcerative colitis.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a traditional Chinese medicine composition for treating ulcerative colitis and a pellet preparation with colon-targeting properties. Background technique [0002] Ulcerative colitis (Ulcerative Colitis, UC), also known as chronic nonspecific ulcerative colitis, is a common autoimmune disease. The main clinical symptoms are recurrent diarrhea, mucus pus and blood, abdominal pain or tenesmus. The course of the disease is protracted and difficult to heal. It lasts for several months to decades. 80% of the patients will have recurrent attacks and the condition will continue to worsen. Patients with a course of 30 years The rate of canceration can be as high as 40%, so it is defined as one of 14 refractory diseases by the World Health Organization (WHO). Ulcerative colitis can occur at any age, but it is more common in 20-40 years old. The incidence rate in my country is about 5-40 / 10...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/718A61K9/16A61K9/52A61P1/04
Inventor 刘继勇岳小强高申朱全刚孙华君
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap